摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Cyano-5-methyl-4-(2-cyano-5-thienyl)-hexanol | 256944-16-8

中文名称
——
中文别名
——
英文名称
4-Cyano-5-methyl-4-(2-cyano-5-thienyl)-hexanol
英文别名
4-Cyano-5-methyl-4-(2-cyano-5-thienyl) hexanol;4-cyano-5-methyl-4-(5-cyano-thien-2-yl)hexanol;4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexanol;4-Cyano-4-(5-cyano-2-thienyl)-5-methylhexanol;5-(3-cyano-6-hydroxy-2-methylhexan-3-yl)thiophene-2-carbonitrile
4-Cyano-5-methyl-4-(2-cyano-5-thienyl)-hexanol化学式
CAS
256944-16-8
化学式
C13H16N2OS
mdl
——
分子量
248.349
InChiKey
PZSXCGFMDLLQRD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    96
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    4-Cyano-5-methyl-4-(2-cyano-5-thienyl)-hexanol1-[2-(3-cyanophenoxy)ethyl]piperazine 在 sodium iodide 、 potassium carbonate三乙胺 作用下, 以 N-甲基乙酰胺乙腈 为溶剂, 以289 mg (0.63 mmol, 77.3%)的产率得到1-[4-cyano-5-methyl-4-(5-cyano-thien-2-yl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine
    参考文献:
    名称:
    NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
    摘要:
    公开号:
    EP1254895B1
  • 作为产物:
    描述:
    [4-Cyano-5-methyl-4-(2-cyano-5-thienyl)hexyloxy]-t-butyldimethylsilane 在 ammonium chloride 、 四丁基氟化铵 作用下, 以 四氢呋喃 为溶剂, 以87.9%的产率得到4-Cyano-5-methyl-4-(2-cyano-5-thienyl)-hexanol
    参考文献:
    名称:
    N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES
    摘要:
    公开号:
    EP1099692B1
点击查看最新优质反应信息

文献信息

  • Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound
    申请人:Eisai Co., Ltd.
    公开号:US20040220193A1
    公开(公告)日:2004-11-04
    The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. 1 In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C 3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R 1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D 1 , D 2 , W 1 and W 2 are the same as or different from each other and each represents a single bond or an optionally substituted C 1-6 alkylene chain.
    本发明提供了一种具有卓越的钙拮抗作用,特别是神经元选择性钙拮抗作用的新化合物。即,提供了下式所示的化合物、其盐或水合物。其中,Ar表示可选取的5-至14-成员芳香环等;环A表示选自哌嗪、同哌嗪、吡啶等任意一环;环B表示可选取的C3-14碳氢环等;E表示单键、由公式—CO—表示的基团等;X表示单键、氧原子等;R1表示氢原子、卤原子、羟基等;D1、D2、W1和W2相同或不同,每个代表单键或可选取的C1-6烷基链。
  • Piperazine compound and pharmaceutical composition containing the compound
    申请人:Yamamoto Noboru
    公开号:US06906072B1
    公开(公告)日:2005-06-14
    The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C 3-14 on hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R 1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D 1 , D 2 , W 1 and W 2 are the same as or different from each other and each represents a single bond or an optionally substituted C 1-6 alkylene chain.
    本发明提供了一种具有优异的钙拮抗作用的新化合物,特别是神经元选择性钙拮抗作用。即,提供了以下式子所表示的化合物,其盐或水合物。在该式子中,Ar表示可选择性取代的5-至14-成员芳香环等;环A表示从哌嗪、同哌嗪、哌啶等中选择的任一环;环B表示可选择性取代的C3-14的碳氢环等;E表示单键、由式子- CO-等表示的基团等;X表示单键、氧原子等;R1表示氢原子、卤素原子、羟基等;D1、D2、W1和W2彼此相同或不同,每个代表单键或可选择性取代的C1-6烷基链。
  • N,N-substituted cyclic amine derivatives
    申请人:Eisai Co., Ltd.
    公开号:US06737425B1
    公开(公告)日:2004-05-18
    The invention provides an N,N-substituted cyclic amine compound represented by the following formula (VIII): wherein A represents an aryl group etc.; E represents a group represented by the formula —CO— or a group represented by the formula —CHOH—; G represents an oxygen atom etc.; J represents an aryl group which may be substituted; R1 represents a lower alkyl group etc.; Alk represents a linear or branched lower alkylene group; n, v, w, x and y are independent of each other and each represents 0 or 1; and p represents 2 or 3, or a pharmacologically acceptable salt thereof. The compound of the present invention or a salt thereof is effective to treat a disease against which calcium antagonism is effective. The disease may include acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral nerve cell death, Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, Huntington disease, cerebral circulatory metabolism disturbance, cerebral function disturbance, pain, spasm, schizophrenia, migraine, epilepsy, maniac-depressive psychosis, nerve degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder (generalized anxiety disorder) and diabetic neuropathy.
    本发明提供了一种由以下公式(VIII)表示的N,N-取代环状胺化合物:其中A代表芳基等;E代表由公式—CO—或公式—CHOH—表示的基团;G代表氧原子等;J代表可能被取代的芳基基团;R1代表较低的烷基等;Alk代表线性或支链较低的烷基烷基;n、v、w、x和y是独立的,每个代表0或1;p代表2或3,或其药学上可接受的盐。本发明的化合物或其盐对钙拮抗作用有效的疾病具有治疗作用。该疾病可能包括急性缺血性卒中、脑卒中、脑梗塞、头部创伤、脑神经细胞死亡、阿尔茨海默病、帕金森病、肌萎缩性侧索硬化、亨廷顿病、脑循环代谢障碍、脑功能障碍、疼痛、痉挛、精神分裂症、偏头痛、癫痫、躁郁症、神经退行性疾病、脑缺血、艾滋病痴呆并发症、水肿、焦虑症(广泛性焦虑症)和糖尿病神经病变。
  • Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP1818326A1
    公开(公告)日:2007-08-15
    The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them: wherein Ar is a thiophene or benzene ring which may be substituted,the ring A is a piperazine ring, homopiperazine ring or piperidine ring which may be substituted, the ring B is a C6-14 aromatic hydrocarbon ring or 5- to 14-membered aromatic heterocyclic ring which may be substituted, the partial structure -D1-E-D2- is a C1-4 alkylene group, W1 and W2 are the same as or different from each other and each represents (1) a single bond or (2) a C1-6 alkylene chain which may be substituted, X is (1) an oxygen atom, a group represented by (2) the formula -NR2- (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted) or (3) -NH-SO2-, R1 is a methyl group, an ethyl group, a n-propyl group or an isopropyl group.
    本发明提供了一种新型化合物,它具有优异的钙拮抗作用,尤其是神经元选择性钙拮抗作用。也就是说,本发明提供了由下式(I)代表的化合物、其盐或它们的水合物: 其中 Ar 是可被取代的噻吩环或苯环,环 A 是可被取代的哌嗪环、均哌嗪环或哌啶环,环 B 是可被取代的 C6-14 芳烃环或 5-14 元芳香杂环,部分结构 -D1-E-D2- 是 C1-4 烯基、W1和W2彼此相同或不同,各自代表(1)单键或(2)可被取代的C1-6亚烷基链,X是(1)氧原子、由(2)式-NR2-(其中R2表示氢原子)代表的基团或C1-6烷基、或 C1-6 烷基、C3-8 环烷基、低级酰基或可能被取代的 C1-6 烷基磺酰基)或 (3) -NH-SO2- 所代表的基团,R1 是甲基、乙基、正丙基或异丙基。
  • US6737425B1
    申请人:——
    公开号:US6737425B1
    公开(公告)日:2004-05-18
查看更多

同类化合物

阿罗洛尔 阿替卡因 阿克兰酯 锡烷,(5-己基-2-噻吩基)三甲基- 邻氨基噻吩(2盐酸) 辛基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 辛基4,6-二溴噻吩并[3,4-b]噻吩-2-羧酸酯 辛基2-甲基异巴豆酸酯 血管紧张素IIAT2受体激动剂 葡聚糖凝胶LH-20 苯螨噻 苯并[c]噻吩-1-羧酸,5-溴-4,5,6,7-四氢-3-(甲硫基)-4-羰基-,乙基酯 苯并[b]噻吩-2-胺 苯并[b]噻吩-2-胺 苯基-[5-(4,4,5,5-四甲基-[1,3,2]二氧杂硼烷-2-基)-噻吩-2-基亚甲基]-胺 苯基-(5-氯噻吩-2-基)甲醇 苯乙酸,-α--[(1-羰基-2-丙烯-1-基)氨基]- 苯乙酰胺,3,5-二氨基-a-羟基-2,4,6-三碘- 苯乙脒,2,6-二氯-a-羟基- 腈氨噻唑 聚(3-丁基噻吩-2,5-二基),REGIOREGULAR 硝呋肼 硅烷,(3-己基-2,5-噻吩二基)二[三甲基- 硅噻菌胺 盐酸阿罗洛尔 盐酸阿罗洛尔 盐酸多佐胺 甲酮,[5-(1-环己烯-1-基)-4-(2-噻嗯基)-1H-吡咯-3-基]-2-噻嗯基- 甲基5-甲酰基-4-甲基-2-噻吩羧酸酯 甲基5-乙氧基-3-羟基-2-噻吩羧酸酯 甲基5-乙基-3-肼基-2-噻吩羧酸酯 甲基5-(氯甲酰基)-2-噻吩羧酸酯 甲基5-(氯乙酰基)-2-噻吩羧酸酯 甲基5-(氨基甲基)噻吩-2-羧酸酯 甲基5-(4-甲氧基苯基)-2-噻吩羧酸酯 甲基5-(4-甲基苯基)-2-噻吩羧酸酯 甲基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 甲基4-硝基-2-噻吩羧酸酯 甲基4-氰基-5-(4,6-二氨基吡啶-2-基)偶氮-3-甲基噻吩-2-羧酸酯 甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 甲基4-{[(2E)-2-(4-氰基苯亚甲基)肼基]磺酰}噻吩-3-羧酸酯 甲基4-(氯甲酰基)-3-噻吩羧酸酯 甲基4-(氨基磺酰基氨基)-3-噻吩羧酸酯 甲基3-甲酰氨基-4-甲基-2-噻吩羧酸酯 甲基3-氨基-5-异丙基-2-噻吩羧酸酯 甲基3-氨基-5-(4-溴苯基)-2-噻吩羧酸酯 甲基3-氨基-4-苯基-5-(三氟甲基)-2-噻吩羧酸酯 甲基3-氨基-4-氰基-5-甲基-2-噻吩羧酸酯 甲基3-氨基-4-丙基-2-噻吩羧酸酯 甲基3-[[(4-甲氧基苯基)亚甲基氨基]氨基磺酰基]噻吩-2-羧酸酯